China-based clinical-stage biotech company Duality Biologics announced on Monday that BeiGene Ltd, a US-based multinational oncology company, has exercised its exclusive option for the B7H4 antibody-drug conjugate (ADC) DB1312/BG-C9074, granting BeiGene global rights for development, manufacturing and commercialization.
DualityBio received an option exercise fee and a milestone payment following the advancement of Phase I dose-escalation in 2024.
In July 2023, DualityBio disclosed an agreement allowing BeiGene to secure a global clinical and commercial license for the investigational ADC targeting select solid tumors. The agreement provided DualityBio with an upfront payment and eligibility for up to USD1.3bn in milestone payments contingent on development, regulatory, and commercial progress. Additional tiered royalties are also included in the agreement.
Kazia Therapeutics updates on paxalisib regulatory pathway after FDA meeting
Veru sells FC2 Female Condom business, focuses on enobosarm
FDA approve Opdivo Qvantig with ENHANZE for subcutaneous use
CARsgen Therapeutics reveals positive CT041-ST-01 (NCT04581473) Phase II clinical trial results
Duality Biologics reveals B7H4 ADC milestone achievement and license exercise by BeiGene
Precigen submits BLA for PRGN-2012 for treatment of recurrent respiratory papillomatosis
Novartis Phase III study of intrathecal onasemnogene abeparvovec meets primary endpoint in SMA
Hemogenyx Pharmaceuticals announces first clinical site for HG-CT-1 Phase I trial
Ondine Biomedical enrolls first patient in US Phase 3 trial
IDEAYA Biosciences enters license agreement with Jiangsu Hengrui Pharmaceuticals
Huadong Medicine collaborates with SynerK
Microtech commences human clinical trial of microsensor platform for heart failure
Ractigen Therapeutics doses first patient in Phase I clinical trial of RAG-17